StemCells announces plans to conduct public sale of shares, warrants

Bookrunner Maxim Group raises funds for general corporate purposes

By Devika Patel

Knoxville, Tenn., March 9 – StemCells Inc. will price a public offering of common stock with two-year and five-year warrants with a 45-day greenshoe, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Maxim Group LLC is the bookrunner.

Proceeds will be used for general corporate purposes, including working capital, capital expenditures, research and development, clinical trials and acquisitions or investments.

StemCells is a clinical-stage biotechnology company based in Palo Alto, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.